ライフサイエンスコーパス: adjunct therapy

1 ction or NO scavengers might be an effective adjunct therapy.

2 llus reuteri to be a promising candidate for adjunct therapy.

3 The patient was treated with clopidogrel as adjunct therapy.

4 ppropriateness of empiric antimicrobials, or adjunct therapies.

5 he potential to take advantage of zinc as an adjunct therapy against CoV-associated diseases.

6 Adjunct therapies and ECMO criteria were the same in the

7 ve care unit, total length of hospital stay, adjunct therapies and procedures, and complications.

8 , development of new antituberculosis drugs, adjunct therapies and vaccines, coupled with visionary p

9 MSCs as an adjunct therapy are safe and can now be explored further

10 There is a need for alternative or adjunct therapies, as resistance to currently used antiv

11 s provide an important proof-of-concept that adjunct therapies can synergize with anti-CD40L Abs to t

12 Adjunct therapy consisting of antiarrhythmic drugs or ra

13 t that plcR may represent a target for which adjunct therapies could be designed for the prevention o

14 f HIV to antiviral compounds, exploration of adjunct therapies directed at host responses in combinat

15 e systemic therapy, but several locoregional adjunct therapies exist.

16 in randomized controlled clinical trials as adjunct therapies for shortening the duration of tubercu

17 argets, thereby aiding in the development of adjunct therapies for the management of HAND, which are

18 Tamoxifen is widely used as an adjunct therapy for breast cancer.

19 ines recommend zinc supplementation as a key adjunct therapy for childhood diarrhea in developing cou

20 est that IL-12 gene therapy could be used as adjunct therapy for coccidioidomycosis.

21 Thus, our vaccine represents a promising adjunct therapy for heroin addiction, providing continuo

22 of GABAA-Rs and/or GABAB-Rs may be a useful adjunct therapy for human islet transplantation.

23 ne administration in AIDS may play a role as adjunct therapy for infections.

24 rmones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bon

25 Intracoronary gamma-radiation used as adjunct therapy for patients with in-stent restenosis si

26 a-Radiation with a 90-yttrium source used as adjunct therapy for patients with ISR results in a lower

27 These results support the use of IFN as an adjunct therapy for patients with PML.

28 er investigation of this compound as a novel adjunct therapy for reperfusion injury.

29 39 enzymatic activity may find utility as an adjunct therapy for secondary hepatic malignancies.

30 d interest in using vitamin D3 (VitD3) as an adjunct therapy for TB because numerous in vitro studies

31 gs suggest that levodopa be considered as an adjunct therapy for the treatment of spastic quadriplegi

32 e transfusion has been used as an aggressive adjunct therapy for this condition.

33 agonists to hPXR may prove to be a promising adjunct therapy for tuberculosis.

34 ptor tyrosine kinase inhibitors, are used as adjunct therapies in a number of cancer treatments.

35 mechanism of action, it may be beneficial as adjunct therapy in CHF patients.

36 inhibition might have clinical utility as an adjunct therapy in management of liver cancer.

37 -36) amide is a safe and efficacious form of adjunct therapy in patients with hyperglycemia in the su

38 ulation, is showing increasing promise as an adjunct therapy in rehabilitation following stroke.

39 ng sepsis and suggest that MDC may aid in an adjunct therapy in sepsis.

40 ion or neutralization of MIF may serve as an adjunct therapy in sepsis.

41 hat early treatment with IL-10 may be useful adjunct therapy in some types of viral encephalitis.

42 al disease over time and can be an important adjunct therapy in the comprehensive treatment of period

43 Vitamin D could be beneficial as an adjunct therapy in the treatment of allergic asthma.

44 Clinically, consideration of antioxidants as adjunct therapy in type 2 diabetes is warranted because

45 hase 2 and 3 trials are underway, and use of adjunct therapies is being explored for drug-sensitive a

46 When used as adjunct therapy, mibefradil did not affect the usual out

47 implications for the potential of VPA as an adjunct therapy not only for cognitively impaired patien

48 identifying a vasoprotecting strategy by the adjunct therapy of 5-FU with Resveratrol.

49 rtant targets relevant to chemoprevention or adjunct therapy of ChC.

50 ynamic therapy looks extremely promising for adjunct therapy of intrahepatic mass lesions.

51 nse, and represent specific interfaces where adjunct therapy or biased ligands may improve beta-agoni

52 pportive care and pain management-analgesia, adjunct therapies, radiotherapy, surgery, systemic antic

53 , ganciclovir and foscarnet combination, and adjunct therapy such as CMV-specific cytotoxic T-lymphoc

54 Adjunct therapies that target spore germination or downs

55 Ideally, neuroscience would inform adjunct therapies that target the neurotransmitter syste

56 The role of nutritional interventions as adjunct therapies to ART merits further investigation.

57 f new, more effective tuberculosis drugs and adjunct therapies to improve treatment outcomes are urge

58 tive agents can and should be re-examined as adjunct therapies to recanalization.

59 We conclude that PBM is a simple adjunct therapy to attenuate the development of diabetic

60 Thus, ADAM II could serve as an adjunct therapy to AZT and NNRTIs that select for L100I

61 r molecular means could serve as a potential adjunct therapy to combat oxidative stress and inhibit t

62 c antagonism of thrombin may be useful as an adjunct therapy to complement inhibition for xenograft r

63 ythmic agents are increasingly being used as adjunct therapy to decrease the frequency of ICD dischar

64 his heterologous axis may hold promise as an adjunct therapy to frontline tuberculosis drugs.

65 ants can offer an achievable and inexpensive adjunct therapy to help inhibit the development of retin

66 cid supplementation represents an achievable adjunct therapy to help prevent vision loss in diabetic

67 icacy and safety of the SGLT-2 inhibitors as adjunct therapy to insulin in T1DM, clinical trials inde

68 ates that SGLT-2 inhibitors are effective as adjunct therapy to insulin in T1DM, heralding improved g

69 candidate therapeutic target and a promising adjunct therapy to PD-1 blockade for the treatment of HI

70 vation of the periphery, and may be a useful adjunct therapy to peripheral nerve repair.

71 Hence, inositol represents a possible novel adjunct therapy to prevent human NTDs.

72 potentially may be used as an alternative or adjunct therapy to standard agents used to treat wound i

73 ient approach may yet prove beneficial as an adjunct therapy to traditional approaches.

74 system and that this can be exploited as an adjunct therapy together with standard drug-based approa

75 Stand-alone atherectomy was attempted, and adjunct therapy was used for residual stenosis.

76 surgical debridement alone or combined with adjunct therapies) were compared.

77 ld be a promising lead for treating VL as an adjunct therapy with miltefosine.

78 Adjunct therapy with tolerogenic nanoparticles represent

79 n and an adenosine diphosphate-antagonist an adjunct therapy with vasodilators and gpIIb/IIIa inhibit